Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Egalet Lines Up Cash In Deal With Japan’s Shionogi Ahead Of IPO

This article was originally published in PharmAsia News

Executive Summary

The specialty pharma will receive $10 million upfront from Shionogi in exchange for rights to multiple oral abuse-deterrent hydrocodone opioid products. The Japanese pharma also agreed to buy $15 million in stock to close with Egalet’s IPO.

You may also be interested in...



European Notebook: U.S. Investors Tap Into Europe; New U.K. Pricing Scheme; Pfizer Dismayed By German Payers

Europe's IPO window remains closed but the region still attracts U.S. investors; drug spending set to decline in Greece and Spain in 2014; Pfizer takes Bosulif off the German market because agreement on price unlikely with health insurers; no room for value-based pricing in the U.K.; European Parliament clears €80 billion in research funding under Horizon 2020.

OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting

There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.

FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake

Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1129788

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel